Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17285747 | 0.71 | NR1H2 (0.47) | NR1H2NR1H3RARBALDH1A1 | |
| SCHEMBL16492725 | 0.68 | NAMPT (0.54) | — | |
| SCHEMBL421514 | 0.68 | BCHE (0.36) | NR1H2NPC1RAB9A | |
| SCHEMBL13103088 | 0.68 | NR1H2 (0.41) | NR1H2NR1H3HPGDALDH1A1HSD17B10 | |
| SCHEMBL4056872 | 0.67 | THRB (0.56) | RARBALDH1A1 | |
| SCHEMBL3785257 | 0.67 | MAPT (0.58) | ALDH1A1 | |
| SCHEMBL8214463 | 0.65 | RARB (0.74) | RARBHPGDALDH1A1HSD17B10 | |
| SCHEMBL25129942 | 0.65 | NR1H2 (0.33) | NR1H2NR1H3 | |
| SCHEMBL16492726 | 0.65 | NAMPT (0.54) | — | |
| SCHEMBL5747846 | 0.65 | CTSK (0.51) | HPGDALDH1A1HSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360107-A1 | AN EIF4A INHIBITOR WITH A NOVEL MECHANISM OF ACTION | UNIV ARIZONA (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2023034813-A1 | AN EIF4A INHIBITOR WITH A NOVEL MECHANISM OF ACTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360107-A1 | AN EIF4A INHIBITOR WITH A NOVEL MECHANISM OF ACTION | EIF4A1, EIF4A2, EIF4A3 | NR1H2 4530/4885NR1H3 4588/4885RARB 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.